NCT06931613View on ClinicalTrials.gov

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions
Relapsed or Refractory Hodgkin LymphomaChildrenNivolumabAutologous Haemopoietic Stem Cell Transplant
Interventions
DRUG

Nivolumab

Nivolumab with or without bendamustine is administered to children prior to auto-HSCT

Trial Locations (2)

196022

Pavlov University, RM Gorbacheva Research Institute, Saint Petersburg

Unknown

N. N. Blokhin Russian Cancer Research Center, Moscow, Russia, Moscow

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER